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Abstract 
Background 
This study sought to correlate faecal and urinary N-methylhistamine (NMH) concentrations 
with resting versus degranulated duodenal mast cell numbers in dogs with chronic 
enteropathies (CE), and investigate correlations between intestinal mast cell activation and 
clinical severity of disease as assessed by canine chronic enteropathy clinical activity index 
(CCECAI), and between urinary and faecal NMH concentrations, mast cell numbers, and 
histopathological scores. Twenty-eight dogs with CE were included. Duodenal biopsies were 
stained with haematoxylin and eosin (H&E), toluidine blue, and by immunohistochemical 
labelling for tryptase. Duodenal biopsies were assigned a histopathological severity score, 
and duodenal mast cell numbers were counted in five high-power fields after metachromatic 
and immunohistochemical staining. Faecal and urinary NMH concentrations were measured 
by gas chromatography–mass spectrometry. 
Results 
There was no correlation between the CCECAI and faecal or urinary NMH concentrations, 
mast cell numbers, or histopathological score – or between faecal or urinary NMH 
concentration and mast cell numbers. Post hoc analysis revealed a statistically significant 
difference in toluidine blue positive mast cells between two treatment groups (exclusion diet 
with/without metronidazole versus immunosuppression (IS), with higher numbers among 
dogs not requiring IS. 
Conclusion 
Faecal and urinary NMH concentrations and duodenal mast cell numbers were not useful 
indicators of severity of disease as assessed by the CCECAI or histological evaluation. The 
number of duodenal mast cells was higher in dogs that did not need IS, i.e. in dogs 
responding to an exclusion diet (with/without metronidazole), than in dogs requiring IS. 
Further studies comparing the role of mast cells in dogs with different forms of CE are 
needed. 
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Background 
Canine chronic enteropathies (CE) are characterised by inflammatory cell infiltration of the 
intestinal lamina propria, the most common of which is lymphoplasmacytic [1,2]. This 
condition can retrospectively be classified into food-responsive disease (FRD), antibiotic-
responsive disease (ARD), and idiopathic inflammatory bowel disease (IBD) according to 
response to treatment [1,3,4]. Clinical markers of disease are sparse to date; few parameters 
have been found to predict the need for immunosuppression (IS) versus diet or antimicrobial 
treatment alone, or to predict refractoriness to treatment and hence prognosis [2,5]. 
Aberrant immune responses against antigens such as the intestinal microbiota or food 
allergens in the intestinal lumen are thought to play a role in the development of canine CE 
[3,6,7]. These aberrant responses may in part be attributable to a type I hypersensitivity 
reaction, which involves degranulation of mast cells in the intestinal mucosa [8]. Moreover, 
mast cells have been suggested to play a role in the pathogenesis of canine and human 
enteropathies and may be a marker of disease severity [8-12]. Studies investigating numbers 
of mast cells in human IBD (i.e. Crohn’s disease (CD) and ulcerative colitis (UC)) have 
found conflicting results [13-16]; possibly reflecting the importance of mast cell activation 
rather than absolute numbers in the mucosa [12]. 
German and colleagues investigated leukocyte subsets in the canine intestine based on 
biopsies obtained from 10 dogs of various breeds with no known enteropathies, providing a 
reference for future studies on mast cell numbers in the canine intestinal mucosa [17]. A few 
years later, the same investigators reported leukocyte subsets in the duodenal mucosa of 27 
dogs with chronic gastrointestinal disease [18]. In the latter study, a lower number of mast 
cells was detected in 9 dogs with idiopathic IBD (excluding FRD and ARD) compared to 11 
dogs with ARD and 23 healthy controls. This was in contrast to Locher et al. [9], who 
reported a higher number of mast cells in the stomach and duodenum in 20 dogs with IBD 
compared to 9 healthy controls. 
Mast cells are bone marrow derived cells reaching maturity within the tissues, with 
characteristic metachromatically staining granules containing inflammatory mediators such as 
heparin and histamine [19]. Cross-linking of IgE molecules on the surface of mast cells leads 
to degranulation and release of the inflammatory mediators, evoking inflammatory changes. 
Once mast cells have released their granules, their ability to stain in a metachromatic fashion 
diminishes. The metachromatic properties of mast cell granules are attributed to heparin, 
accounting for the difficulties identifying mast cells that have released the contents of their 
granules. However, monoclonal antibodies for tryptase and chymase are able to identify small 
amounts of these mast cell-specific proteases, providing a method for detecting even 
degranulated (i.e. activated) mast cells [12]. The content of tryptase versus chymase in mast 
cells varies between tissue localisation [20]. In the human and canine gastrointestinal tract, 
mast cells that only contain tryptase (MCT) have been shown to outnumber cells containing 
both tryptase and chymase (MCTC), or cells only containing chymase (MCC) [9,10,20,21]. 
These findings suggest that monoclonal antibodies for tryptase most accurately identify 
activated intestinal mast cells. 
As the quantification of intestinal mast cell numbers is difficult, serum markers for the 
detection of mediators released from mast cells have been described. Histamine is one of the 
major inflammatory mediators released from activated mast cells, and histamine 
concentrations may directly reflect the degree of mast cell activation [22]. However, 
histamine in serum is rapidly metabolised to form N-methylhistamine (NMH) and imidazole 
acetaldehyde [23]. Due to the short half-life of serum histamine [24], measurement of 
metabolites in body excretions (urine and faeces) is considered to more accurately reflect the 
overall mast cell activity [23]. Moreover, NMH is an easily measurable parameter that can be 
analysed in specimens obtained by non-invasive means, i.e., in faeces or voided urine [25]. A 
gas chromatography–mass spectrometry (GC-MS) method for measurement of NMH 
concentrations in canine urine samples and faecal extracts has recently been validated [25]. 
There is increasing evidence that NMH concentration is elevated in the urine and faeces of 
some dogs with gastrointestinal disease, such as racing sled dogs with gastro-intestinal 
ulcerations [26], Lundehunds with protein-losing enteropathy [27], and in dogs with CE [28]. 
Further, it has been shown that NMH concentrations are increased in plasma and urine of 
humans with IBD – with higher concentrations associated with a higher clinical activity 
index, and decreasing concentrations corresponding to clinical remission following therapy 
[29,30]. Only one study has so far investigated a possible correlation between severity of 
clinical disease and histamine concentrations in canine CE [28]. An increase in faecal NMH 
was found in dogs with chronic gastrointestinal disease compared to healthy controls, and one 
quarter of the dogs with CE had increased urinary NMH. However, concentrations did not 
correlate with severity of disease as assessed by the canine chronic enteropathy clinical 
activity index (CCECAI) [5]. 
The aim of the present study was to correlate faecal and urinary NMH concentrations with 
resting (i.e., metachromatically staining) versus degranulated (i.e., identified by monoclonal 
tryptase antibodies) duodenal mast cell numbers, hypothesising that urinary and/or faecal 
NMH concentrations would increase with increasing mast cell degranulation and hence serve 
as markers for mast cell activity. We further sought to investigate possible correlations 
between mast cell activation (assessed by degranulation and NMH concentrations) and 
clinical disease activity index (CCECAI), hypothesising that we would find evidence of 
increased mast cell activity in patients with clinically more severe disease. Finally, we 
investigated the relationship between both NMH concentrations and mast cell numbers versus 
histopathological scores, the latter assessed according to the standards defined by the World 
Small Animal Veterinary Association (WSAVA) Gastrointestinal Standardization Group 
[31]. 
Materials and methods 
Selection of cases 
The archived serum and histology samples for this study have been taken for diagnostic 
purposes only and are residual samples already stored and available in the Royal Veterinary 
College (RVC) archive. They were originally obtained with informed owner consent under 
the Veterinary Surgeons Act (residual clause) and approved by the RVC Ethics and Welfare 
Committee. The Clinical Investigations Centre at the RVC has archived samples from dogs 
with CE since 2005; consisting of serum, plasma, urine, faeces, gastrointestinal biopsies, or 
any combination thereof. An identification number labels all samples, allowing retrospective 
review of clinical data from the Queen Mother Hospital for Animals’ electronic and/or paper 
records. The enteropathy archive was searched for dogs with a final diagnosis of CE for 
which urine, faeces, duodenal biopsies, and clinical data were available. Previously reported 
groups of clinically healthy dogs were used as controls for establishing control ranges for 
urinary and faecal NMH concentrations (n = 6 and n = 49, respectively) [25,28]. 
Clinical diagnosis and laboratory methods 
All dogs selected for the study had presented to the Queen Mother Hospital for Animals 
(QMHA) with a chronic (3 weeks or more) history of vomiting and/or diarrhea. Exclusion of 
extra gastrointestinal disease as a cause of the presenting signs was based on results from 
routine blood work (hematology and serum biochemistry), urinalysis, faecal parasitology, 
endocrine tests (basal cortisol or ACTH stimulation test), serum trypsine-like 
immunoreactivity, and abdominal ultrasound examination. Gastroduodenoscopy was 
performed in all dogs, and duodenal biopsies were fixed in phosphate-buffered formalin 
solution followed by paraffin embedding. Clinical disease activity index (expressed as 
CCECAI) was assigned to each dog at the time of presentation (n = 6) or retrospectively by 
review of paper and electronic records (n = 22) by one of the investigators (KPA) [5]. All 
clients seen at the QMHA are asked questions based on a standardised questionnaire, 
facilitating retrospective determination of the CCECAI. Treatments were initiated step-wise 
according to clinician preference at the time, and were recorded as exclusion diet (i.e. novel 
or hydrolysed protein diet fed exclusively), antimicrobial therapy (metronidazole), and/or 
immunosuppressive therapy (prednisolone, azathioprine, and/or cyclosporine). 
Duodenal biopsies were stained with haematoxylin and eosin (H&E) for routine 
histopathological evaluation – all of which were examined by board certified pathologists at 
the time of the initial investigation. A single board certified pathologist (SP), blinded to all 
other information about the dogs, reassessed the duodenal biopsies to provide a 
histopathological score according to the standards set by the WSAVA Gastrointestinal 
Standardization Group [31]. 
Metachromatic staining with toluidine blue was performed as described elsewhere [12] 
(Figure 1). Immunohistochemical staining for mast cell tryptase was performed using an 
automated staining machine (Leica BondMax) and amplification kit (Leica Refine), 
according to the standard immunohistochemical protocol used in the RVC Diagnostic 
Laboratory (Figure 2). Briefly, 4 μm sections of duodenal mucosa were pretreated with a pH 
9.0 retrieval solution (Dako Epitope Retrieval 2 solution, Dako, Ely) for 10 minutes then a 
mouse anti-human mast cell tryptase monoclonal antibody (Dako) was used at a 1:800 
dilution. Sections were counterstained with haematoxylin. 
Figure 1 Duodenal section from a dog with chronic enteropathy stained with toluidine 
blue for metachromatic staining of mast cells (×200). Purple cells represent mast cells. Bar 
= 100 μm. 
Figure 2 Duodenal section from a dog with chronic enteropathy labelled 
immunohistochemically with anti-human mast cell tryptase (×200). Brown cells represent 
mast cells. Bar = 100 μm. 
Numbers of mucosal mast cells were assessed in duodenal biopsies by metachromatic 
staining (toluidine blue; MCTB) and by immunohistochemical labelling for tryptase (MCT) 
[21]. Duodenal mast cell numbers were counted in five high-power fields (×40) for each dog 
and each staining method by one of the authors (KPA). 
Faecal and urine samples (either voided or collected by cystocentesis) from all dogs were 
frozen at −80°C, for up to 2.5 years, until further analysis. Faecal and urinary NMH 
concentrations were determined by GC-MS as described elsewhere [25,32]. The assay has 
previously been analytically validated for use in dogs at the Texas A&M Gastroenterology 
Laboratory [25]. 
Statistical analyses 
Spearman’s rank correlation coefficient was calculated to assess correlation between faecal 
and urinary NMH concentrations with clinical severity of disease (expressed as CCECAI) 
and histological severity of disease (expressed as WSAVA score), and between mast cell 
numbers and clinical and histological severity of disease. Normality was assessed by the 
Shapiro Wilk test. For non-normally distributed data, Mann–Whitney U test was used for 
comparison of mast cell numbers and NMH concentrations between treatment groups (diet 
and/or antimicrobials versus immunosuppressive treatment). T-test was used for normally 
distributed data. Statistical significance level was set at P < 0.05. 
Results 
Between November 2005 and August 2011, samples from 259 dogs with a recorded diagnosis 
consistent with CE (e.g. IBD, enteropathy, protein-losing enteropathy, food-responsive 
enteropathy, gastroenteritis) were archived. For 32 of these dogs, urine, faeces, and duodenal 
biopsy samples were recorded to be available. Retrospective review of records from these 
dogs led to exclusion of one dog due to a final diagnosis of histiocytic ulcerative colitis. 
Another 3 dogs were excluded due to concurrent severe extra-intestinal disease, with 
potentially overlapping clinical signs (renal lymphoma, hepatic lymphoma, and immune-
mediated haemolytic anaemia). The final study population consisted of 28 dogs, 21 of which 
had all samples (duodenal biopsies, urine and faeces) present in the archive. (Duodenal and 
faecal samples were available from 24 dogs each; from 1 dog both faecal and duodenal 
samples were missing). 
Median age of the dogs of the study population was 4 years (range: 13 months-10 years); 13 
females (10 spayed) and 15 males (9 castrated). Eight breeds were represented including 8 
Labrador retrievers, 3 German shepherd dogs, 2 Cocker spaniels, 2 Cross breed dogs, and one 
each of: Cavalier King Charles spaniel, Siberian Husky, Keeshond, Staffordshire Bull terrier, 
Jack Russell terrier, Yorkshire terrier, Greyhound, Newfoundland, Weimaraner, Utagon, 
Dogue de Bordeaux, Golden retriever, and Miniature schnauzer. 
Median urinary NMH concentration was 97 ng/mg creatinine (range 5–249 ng/mg 
creatinine), and median faecal NMH concentration was 48 ng/g (range 0–1,451 ng/g) (Table 
1). These concentrations were within the normal range (0–136 ng/mg creatinine for urinary 
NMH and 0–191 ng/g for faecal NMH) [25,28], and not significantly different from the 3-day 
mean faecal NMH concentrations previously reported in 49 healthy control dogs (53 ng/g, 
range 9–252 ng/g) [28]. Six dogs had urinary NMH concentrations above the upper limit of 
the reference interval, and 4 dogs had faecal NMH higher than the upper limit of the 
reference interval; 2 dogs had both urinary and faecal NMH concentrations above the upper 
limit of the reference interval. Median CCECAI was 6 (range 2–13), and median 
histopathology score 2 (range 0–9). In 2 dogs (with histopathology scores of 0 and 4), the 
duodenal biopsies were of inadequate quality as defined by the WSAVA Gastrointestinal 
Standardization group, and these biopsies were excluded from further analyses of 
histopathological severity. 
Table 1 Summary of clinical and clinicopathological data in 28 dogs with chronic enteropathy 
Dog Age (years) Sex CCECAI Therapy Fecal NMH Urinary NMH Mast cells (mean number/10 hpf) Histopathology duodenum 
≤191(ng/g) ≤136(ng/mg creatinine) TB IHC WSAVA score Infiltrate 
1 9y 4 m FN 12 D, IS 74 176 16.6 31.4 3 LP 
2 1y 5 m MN 6 D, M - 46 3.2 21 0 N/A 
3 3y 8 m MN 5 D, M 40 86 22.6 22.6 1 LP 
4 2y 1 m F 7 D, M 0 32 2 16 1 neut 
5 1y 3 m M 5 D - 474 1.4 10 0 N/A 
6 10y MN 9 D, M - 69 11.6 16.4 3 LP 
7 1y 6 m FN 6 D, IS 165 108 1.2 2.6 0 N/A 
8 7y 9 m FN 7 D, M, IS 789 186 2.6 13.4 2 - 
9 5y 8 m MN 9 D 57 132 9.2 28 0 N/A 
10 3y 1 m MN 3 D, M 139 95 10 11.8 1 - 
11 6y 5 m MN 4 D 1451 62 6.4 10.2 5 LP, eos 
12 2y 7 m MN 6 D, M 0 249 8 27.4 5 eos 
13 4y 11 m FN 7 D, IS 54 112 2.2 2 1 - 
14 8y M 13 D, M 272 114 3.8 9.8 4 LP 
15 2y 6 m M 7 D, M 98 68 1.6 12.2 5 LP* 
16 4y F 8 D, IS 1150 163 0.2 8.6 5 eos 
17 4y 4 m M 9 D, IS 29 19 1 4.2 1 - 
18 3y 10 m FN 6 D 0 53 0.4 7.8 2 LP 
19 1y 1 m MN 5 D 0 100 8.8 4.2 9 LP, eos** 
20 1y 2 m MN 5 D 0 99 3.6 9.2 1 - 
21 6y 2 m FN 9 D, IS 0 43 0.1 1.2 3 LP 
22 3y 3 m FN 2 D 0 46 0.4 2.2 3 LP* 
23 6y 6 m M 6 D 131 53 2.8 10.4 6 LP 
24 8y 2 m FN 9 D 105 5 9.2 6.6 0 N/A 
25 4y 5 m M 11 D, IS 41 76 - - - - 
26 1y 1 m F 6 D, M, IS - 52 - - - - 
27 8y 7 m FN 4 IS 0 116 - - - - 
28 4y FN 6 D, M 38 151 - - - - 
Median   6  47.5 90.5 3 10.1 2  
Min   2  0 5 0.1 1.2 0  
Max   13  1451 474 22.6 31.4 9  
CCECAI, canine chronic enteropathy clinical activity index; NMH, N-methylhistamine; hpf, high-power field; TB, toluidine blue; IHC, immunohistochemistry (tryptase); 
WSAVA, World Small Animal Veterinary Association; FN, female neutered; MN, male neutered; D, diet (novel or hydrolysed protein); M, metronidazole; IS, 
immunosuppressive drug (prednisolone, azathioprine, cyclosporine); LP, lymphoplasmacytic; neut, neutrophilic; eos, eosinophilic; *, moderate; **, marked; N/A, not 
applicable; − data missing. 
There was no correlation between the CCECAI and faecal or urinary NMH concentrations 
(Spearman’s rho 0.23 and −0.032, respectively), mast cell numbers (MCTB or MCT; rho 
−0.004 and 0.04, respectively), or histopathology score (rho −0.103). Furthermore, there was 
no correlation between faecal (rho 0.05 and −0.001 for MCTB and MCT, respectively) or 
urinary (rho 0.18 and 0.26 for MCTB and MCT, respectively) NMH concentration and mast 
cell numbers, nor was there any correlation between urinary and faecal NMH concentrations 
(rho 0.22). 
Treatment initiated or advised by clinicians at the QMHA was recorded for each dog, and 
consisted of an exclusion diet with (n = 9) or without (n = 9) metronidazole, or IS (n = 10; 
these dogs had failed treatment trials with diet and metronidazole, either prior to or after 
referral to the QMHA). Biopsies from 4 of the dogs (3 treated with IS, one with diet and 
metronidazole) were missing from the archive. Due to the low number of dogs, assessment of 
differences between treatment groups was not attempted in this study. However, the data 
gave an impression of higher numbers of mast cells detected in duodenal biopsies from dogs 
in which IS therapy was not necessary; i.e. dogs responding to an exclusion diet with or 
without metronidazole. Post hoc analysis revealed that dogs eventually requiring 
immunosuppressive therapy had more MCTB (P = 0.041) in their pre-treatment biopsies than 
those responding to an exclusion diet, with or without metronidazole, (Figure 3). There was 
no statistically significant difference between these groups for numbers of MCT (P = 0.105; 
Figure 4), and there was no difference between numbers of MCTB in dogs treated with an 
exclusion diet and metronidazole versus an exclusion diet alone (P = 0.41; Figure 5). Faecal 
and urinary NMH concentrations did not differ between treatment groups (P = 0.52 and P = 
0.95, respectively). 
Figure 3 Median numbers of MCTB in 5 high power fields (×40) for 24 dogs with chronic 
enteropathy, grouped based on treatment. IS = treated by immunosuppression; Metr = 
treated with metronidazole. Lines represent median and interquartile range. 
Figure 4 Median numbers of MCT in 5 high power fields (×40) for 24 dogs with chronic 
enteropathy, grouped based on treatment. IS = treated by immunosuppression; Metr = 
treated with metronidazole. Lines represent median and interquartile range. 
Figure 5 Median numbers of MCTB in 5 high power fields (×40) for 24 dogs with chronic 
enteropathy, separated by treatment group. IS = treated by immunosuppression; Metr = 
treated with metronidazole. Lines represent median and interquartile range. 
Discussion 
We were unable to find a correlation between intestinal mast cell numbers and clinical 
severity of disease as assessed by CCECAI based on the dogs enrolled in this study. Previous 
studies assessing mast cell numbers in dogs with various enteropathies have yielded 
conflicting results, which may be partially explained by differences in fixation and/or staining 
techniques [3,33]. More specifically, it has been postulated that mast cell degranulation with 
release of inflammatory mediators could explain a decrease in detectable mast cells in 
diseased tissue, as degranulated mast cells stain poorly [3,12]. Immunolabelling for mast cell 
proteases (i.e. tryptase and/or chymase) enables identification of degranulated cells. A 
decrease in metachromatically staining mast cells in combination with a constant to 
increasing number of tryptase positive mast cells in patients with inflammatory intestinal 
disease would support a role of mast cell mediators in that particular patient. Therefore, we 
investigated the number of both metachromatically staining mast cells (MCTB) and of MCT. 
The lack of correlation between either of these and CCECAI could suggest that mast cells 
and mast cell mediators are not major contributors to the clinical signs observed in canine 
patients with CE. 
Studies investigating the numbers of mast cells in human patients with IBD (i.e. CD and UC) 
have also reported conflicting results. Dvorak et al. [13] identified mast cells by electron 
microscopy and found increased numbers of mast cells in the ileal mucosa of patients with 
CD compared to healthy controls. Nishida et al. [15] utilised immunohistochemical staining 
for tryptase and described higher mast cell numbers in patients with both CD and UC than in 
healthy controls. In contrast, Nolte et al. [34] reported increased numbers of mast cells in 
patients with UC, but similar numbers in those with CD, when comparing metachromatically 
staining mast cells in humans with IBD to healthy controls. Mast cell numbers were higher in 
inflamed tissue than normal tissue from both patient groups. Balász et al. [14] also reported 
higher numbers of metachromatically staining mast cells in patients with active UC than in 
patients in remission. In contrast, King et al. [16] found a decreased number of mast cells in 
areas of active inflammation in patients with UC compared to normal colonic mucosa from 
the same individuals. 
The discrepancies in both human and canine studies may partially be explained by different 
staining techniques, resulting in a variable ability to identify intact versus degranulated mast 
cells [35]. More specifically, mast cell degranulation could explain why German et al. [18] 
found decreased numbers of mast cells identified by toluidine blue in dogs with IBD, whereas 
Locher et al. showed numbers of duodenal tryptase positive mast cells to be increased in dogs 
with this condition [3,9]. Bearing this in mind, Kleinschmidt et al. [10] sought to identify the 
number of metachromatically staining mast cells (using kresylecht-violet; MCKEV) versus 
tryptase and/or chymase positive mast cells (MCtotal) in dogs with inflammatory enteropathies 
versus controls. Although their findings generally showed a decrease in mast cell numbers in 
diseased dogs, they identified higher numbers of MCtotal versus MCKEV in 14 of 19 small 
intestinal samples from inflamed areas in affected dogs, whereas this was the case for only 8 
of 20 unaffected areas of the small intestine from these patients, suggesting an association 
between mast cell activation and intestinal inflammation in this population of dogs. 
Post hoc analysis of the data in this study revealed higher numbers of MCTB in dogs treated 
with an exclusion diet (with or without antimicrobial treatment) versus dogs requiring IS to 
control clinical signs in our study population (P = 0.041), supporting a role of mast cell 
infiltration and activation in this subset of dogs with CE. The low number of cases can most 
likely explain lack of a statistically significant difference between numbers of MCT. 
However, the latter could also suggest increased mast cell activation (leading to lower 
numbers of MCTB) in dogs requiring IS. Interestingly, German et al. reported similar findings 
in 27 dogs with CE [18]. Dogs classified as having IBD (i.e. requiring IS) had significantly 
lower numbers of MCTB than dogs with ARD, and dogs with FRD appeared to have similar 
numbers of MCTB as the dogs with ARD; lack of a significant difference between dogs in the 
dogs with FRD and IBD in our study could be due to a low number of dogs with FRD (n = 6). 
Lower amounts of IgE antibodies detected in the faeces of Soft Coated Wheaten Terriers fed 
an exclusion diet, and peak faecal IgE levels measured following feeding with a provocative 
diet, lends some support to the theory that mast cell activation may be involved in the 
pathogenesis of FRD [36]. 
Using similar techniques as the present study for metachromatic staining (toluidine blue) and 
counting of duodenal mucosal mast cell numbers, Berghoff et al. [28] reported a median mast 
cell count of 4.4 per high-power field (range 0–17, n = 11) in dogs with CE. These numbers 
are similar to ours, and in line with our findings, the degree of mast cell infiltration did not 
correlate with the urinary or faecal NMH. Their study did not include information about 
treatment, precluding any such comparisons. 
In accordance with previous studies, we did not find any correlation between CCECAI and 
the histopathological score – underlining the need for additional markers of clinical disease 
and response to treatment [37,38]. In human patients with IBD (CD or UC), urinary NMH 
has been correlated to clinical disease activity and severity of lesions observed by endoscopy, 
with increased urinary NMH concentrations corresponding to active disease, and urinary 
NMH concentrations during clinical remission being similar to those of healthy controls 
[29,30]. In our study, neither urinary nor faecal concentrations of NMH correlated with 
clinical disease activity (CCECAI), and in contrary to mast cell numbers, there was no 
difference in urinary or faecal NMH concentrations between treatment groups. This could 
again reflect low numbers of cases. Moreover, it is likely that mast cell activation and release 
of histamine play a role only in a subgroup of dogs, further decreasing the power of our 
study, as we included dogs with ARD, FRD, and IBD. Finally, we cannot exclude inaccurate 
results due to decay of urinary and faecal NMH during storage, although there was no 
indication of lower values found in the older compared to the newer samples (data not 
shown). 
Previous studies have suggested a role of histamine release in select groups of dogs with 
enteropathy. Vaden et al. [39] reported decreased release of histamine from jejunal mast cells 
following in vitro stimulation of biopsies from Soft Coated Wheaten Terriers with protein-
losing enteropathy and/or –nephropathy, and postulated that this could reflect depletion of 
histamine due to ongoing degranulation. Berghoff et al. [27] found increased faecal NMH 
concentrations in Norwegian Lundehunds with chronic gastrointestinal disease compared to 
healthy controls and also in racing Alaskan sled-dogs, prone to gastrointestinal ulceration, 
compared to working Retrievers [26]. These findings were followed up by the first study 
investigating a potential correlation between faecal and urinary NMH concentrations and 
clinical severity of disease in dogs with CE [28]. In line with our findings, there was no 
correlation between faecal and urinary NMH, or between either faecal or urinary NMH 
concentrations and the CCECAI scores. However, dogs with CE had higher mean 
concentrations of faecal NMH than healthy control dogs, and 4/16 dogs had increased urinary 
and faecal NMH concentrations (only 1 dog had an increase in both). The authors suggested 
that histamine release was likely to play a role in some dogs with CE. Interestingly, the 4 
dogs with increased urinary NMH concentrations all had moderate inflammatory infiltrate in 
the duodenal mucosa, whereas the inflammatory changes in the 12 dogs with normal urinary 
NMH were moderate in one and mild in the remaining dogs. These findings contrast ours, as 
none of the dogs with moderate or marked duodenal mucosal inflammation (dog number 15, 
19, 22) had increased urinary NMH. This discrepancy could be due to the low number of 
cases in both studies, and in particular, the generally mild histopathological changes in our 
population. The proportion of dogs with increased faecal or urinary NMH in our study (17 
and 21%, respectively) was comparable to the 25% reported by Berghoff et al. [28]. 
In our study, incorporating a histopathology score and mast cell numbers unfortunately did 
not help to elucidate the potential clinical utility of measuring NMH, as neither faecal nor 
urinary NMH concentrations correlated with mast cell numbers or histopathological severity. 
However, it did lend some support to mast cell infiltration playing a role in a subgroup of 
dogs with CE – revealing a higher number of mast cells by metachromatic staining (MCTB) in 
dogs with FRD and ARD. As there was no significant difference in numbers of MCT, 
increased degranulation in dogs with IBD could not be ruled out, but this finding was thought 
to more likely be due to low numbers and hence lack of power to detect a difference in this 
group. 
Another limitation of this study, was that only endoscopically obtained duodenal biopsies 
were available. It is possible that a correlation between NMH concentrations and clinical 
severity (CCECAI) or mast cell numbers could have been detected if jejunal, ileal and/or full-
thickness biopsies had been available for analyses. Recent studies have shown histological 
discrepancies between duodenal and ileal samples from dogs with CE, and indicated a higher 
frequency of ileal versus duodenal lesions – although the number of mast cells were not 
assessed in these studies [38,40]. Kleinschmidt et al. [10] utilised full-thickness biopsies from 
all segments of the canine gastrointestinal tract to assess intestinal mast cell numbers and 
distribution. These investigators described lower mast cell numbers in the submucosa than 
the lamina propria, rendering the absence of deeper layers (i.e. the submucosa and 
muscularis) in the biopsies an unlikely cause of our negative findings. However, in dogs with 
lymphoplasmacytic enteritis, lower numbers of MCT were reported in the duodenum and 
jejunum compared to the ileum. Including assessment of ileal biopsies would have 
strengthened the present study, but was not feasible due to its retrospective nature. 
Conclusions 
Our study did not show any correlations between urinary or faecal NMH concentrations and 
clinical disease severity or numbers of intestinal mast cells. However, there was a trend of 
increased numbers of intestinal mast cells in dogs responding to diet and/or antimicrobial 
therapy compared to those requiring IS. Further studies designed to look at differences in 
intestinal mast cells between dogs with the three major forms of CE (FRD, ARD, and 
idiopathic IBD) are required to investigate the significance of this observation. 
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